IU Health will refund $280,000 to Medicare
Indiana University Health will refund the federal Medicare program $280,000 after an audit of almost 200 claims made by its downtown hospitals found nearly 18 percent of them had been billed improperly.
Health Care & Life Sciences
Articles
Price pressures could ground Lilly’s growth
Most analysts agree with Eli Lilly and Co.’s prediction that, after tough years from 2012 to 2014, the drugmaker will begin growing sales and profits again. But in a new report, BMO Capital Markets predicts Lilly will get stuck at a reduced level of revenue and profit in 2014 and stay there for years.
Potential Effient rival recommended for approval
Johnson & Johnson and Bayer AG’s blood-thinner Xarelto should be approved to help prevent heart attacks and strokes in patients with a common condition, a U.S. regulatory report recommended.
Good cholesterol may not lower heart risk, study suggests
Raising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
U.S. losing drug-research jobs to other countries
Eli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore, Ireland and South Africa boost incentives.
Lilly unlikely to gain from Plavix patent loss, analyst says
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
WellPoint protestors harass Braly as political disclosure proposal fails
The proposal, which sought twice-yearly reports on all the health insurer’s donations used for political campaigns or lobbying, was overwhelmingly voted down by WellPoint shareholders.
Activists plan to protest WellPoint political giving at meeting
A mix of union groups, activist investors and single-payer advocates will call for increased disclosure from WellPoint, and some investment funds will vote against WellPoint board members who they say have failed to exercise proper oversight of WellPoint’s political spending.
Justices grill both sides in IU Health case
Much of the nearly 45 minutes of arguments and questioning on May 10 involved the justices and the lawyers for both parties trying unsuccessfully to apply various scenarios from the retail world of commerce to health care pricing.
Indiana slips in life sciences funding
Indiana has taken “a giant step backward” in the availability of early-stage capital for life sciences companies, according to the Indiana Health Industry Forum—which also has a few ideas on how to reverse those developments.
Purdue looks to new clinic to cut health costs
Purdue University's trustees approved plans Friday for a new campus medical clinic that administrators expect eventually will cut the school's health care costs for employees and their families.
SCHREIBER: Innovation will drive health care industry
Entrepreneurship needs broader encouragement, and is targeted in a new plan.
OBEIME: Poor, uninsured won’t monopolize resources
Myth prevents policymakers from attacking real problem of distributing funding.
TITTLE: Big challenges loom for nursing facilities
Boom in elderly population and falling reimbursements expected to cause squeeze.
More physicians using social media to find jobs
But major Indianapolis-area hospitals still prefer personal referrals
Companies adopting unlimited time-off policies
Proponents of such policies say they are the future of work—even as they acknowledge that it may take a generation for them to be widely accepted. Some workers, however, are fearful.
Roche scraps hoped-for cholesterol blockbuster
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing a similar drug.
Lilly: Forget Alzheimer’s; think diabetes
For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.
State’s high court to weigh hospital bills
The Indiana Supreme Court this week will consider whether hospital billing practices should be put on trial. The state’s highest court will hear oral arguments Thursday in a case in which two uninsured patients have sued Indiana University Health for charging them much higher prices than it would have charged insured patients.